PHENAZOPYRIDINE HCL Tablet Maximum Strength
- Manufacturer
- Safrel Pharmaceuticals, LLC.
- Effective date
- 2022-08-01
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 1
- Source
- full-release
- Hydrated at
- 2026-05-31 23:50:24
Label at a glance#
Contacts and useful links#
Label contents#
Full prescribing information#
OTC - ACTIVE INGREDIENT SECTION
Active ingredient (in each tablet)
Phenazopyridine Hydrochloride 99.5 mg
OTC - PURPOSE SECTION
Purpose
Urinary Tract Analgesic
OTC - KEEP OUT OF REACH OF CHILDREN SECTION
Keep out of reach of children. In case of an overdose, get medical help or contact poison Control Center right away.
INDICATIONS & USAGE SECTION
Use Relief from urinary pain, burning, urgency and frequency associated with urinary tract infections.
WARNINGS SECTION
Please read insert for important precautions.
Ask a doctor before use if you have:
■ kidney disease
■ allergies to foods, preservatives or dyes
■ had a hypersensitive reaction to Phenazopyridine Hydrochloride
Do not use if you have Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency unless approved by your physician.
When using this product
■ stomach upset may occur, taking this product with or after meals may reduce stomach upset
■ your urine will become reddish-orange in color. This is not harmful, but care should be taken to avoid staining clothing or other items.
Stop use and ask a doctor if
■ your symptoms last for more than 2 days
■ you suspect you are having an adverse reaction to the medication
■ Long-term adminitration of phenazopyridine hydrochloride has induced neoplasia in rats (large instestine) andmice (liver). Although no association between phenazopyridine hydrochloride and human enoplasia has beeen reported, adequate epidemiological studies along these lines have not been conducted.
If pregnant or breast-feeding, ask a health professional before use. A pregnancy test and consultation with a health professional if pregnancy is confirmed is recommended prior to use.
Keep out of reach of children. In case of an overdose, get medical help or contact a Poison Control Center (1-800-222-1222) right away.
OTHER SAFETY INFORMATION
■ This product can interfere with laboratory tests including urine, glucose (sugar), and ketones tests
■ This product may stain contact lenses and other items if handled after touching tablets
■ long term administration of phenazopyridine HCI has induced neoplasia in rats (large intestine) and mice (liver). Although no association between phenazopyridine hydrochloride and human neoplasia has been reported, adequate epidemiological studies along these lines have not been conducted
■ Store at room temperature 15°-30°C (59°-86°F) in a dry place and protect from light
DOSAGE & ADMINISTRATION SECTION
■ Adults and children 12 years of age and over: Take 2 tablets 3 times daily with or after meals as needed for up to two days. Take with a full glass of water. Do not use for more than 2 days (12 tablets) without consulting a doctor
■ Children under 12: Do not use wihout consulting a doctor
INACTIVE INGREDIENT SECTION
pregelatinized starch, microcrystalline cellulose, maize (corn) starch, povidone, croscarmellose sodium, magnesium stearate, colloidal silicon dioxide, hydroxypropyl methylcellulose, polyethylene glycol
OTC - QUESTIONS SECTION
call toll-free 1-845-547-2667
SPL UNCLASSIFIED SECTION
Size and color of tablets may vary.
*This product is not manufactured or distributed by the owner of the registered trademark AZO Urinary Pain Relief®.
Distributed by: Safrel Pharmaceuticals, LLC
Bridgewater, NJ 08807
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
Compare to the active ingredient in AZO Urinary Pain Relief® Maximum Strength*
MAXIMUM STRENGTH
Urinary Pain Relief
PHENAZOPYRIDINE HYDROCHLORIDE 99.5 mg
Quickly eases urinary pain, burning & urgency
• More active ingredient for maximum relief
• Provides targeted relief for urinary pain
NDC 71309-779-72 - 72 Count
NDC 71309-779-28- 28Count
DailyMed RxNorm Mappings#
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 71309-779-28 | 2024-01-30 | C162847 | 48780-1 | 1030e365-2321-111a-e063-dadaa90a10e2 | PHENAZOPYRIDINE HCL Tablet Maximum Strength |
| 71309-779-72 | 2024-01-30 | C162847 | 48780-1 | 1030e365-2321-111a-e063-dadaa90a10e2 | PHENAZOPYRIDINE HCL Tablet Maximum Strength |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 71309-779-28 | Urinary Pain Relief | 28 in 1 BOTTLE | TABLET | 28 | 1 | |
| 71309-779-72 | Urinary Pain Relief | 72 in 1 BOTTLE | TABLET | 72 | 1 |
DailyMed Dashboard NDC Coverage#
Products#
Every source-derived product name is available through these pages.
- Urinary Pain Relief
- Phenazopyridine Hydrochloride
- MAGNESIUM STEARATE
- HYPROMELLOSE, UNSPECIFIED
- STARCH, CORN
- POLYETHYLENE GLYCOL 400
- CELLULOSE, MICROCRYSTALLINE
- POVIDONE K30
- CROSCARMELLOSE SODIUM
- PHENAZOPYRIDINE
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 71309-779 | 71309-779-72, 71309-779-28 |
Ingredients#
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| MAGNESIUM STEARATE | 70097M6I30 | IACT |
| HYPROMELLOSE, UNSPECIFIED | 3NXW29V3WO | IACT |
| STARCH, CORN | O8232NY3SJ | IACT |
| POLYETHYLENE GLYCOL 400 | B697894SGQ | IACT |
| CELLULOSE, MICROCRYSTALLINE | OP1R32D61U | IACT |
| POVIDONE K30 | U725QWY32X | IACT |
| CROSCARMELLOSE SODIUM | M28OL1HH48 | IACT |
| PHENAZOPYRIDINE HYDROCHLORIDE | 0EWG668W17 | ACTIB |
Source Document#
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| e60ddefb-fd5e-b5df-e053-2a95a90a1b89 | e60ddbd8-5350-19e0-e053-2995a90ac67a | 2022-08-01 | Warnings | e60ddefb-fd5e-b5df-e053-2a95a90a1b89 e60ddbd8-5350-19e0-e053-2995a90ac67a |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.

